Company
SAB Biotherapeutics Inc (NASDAQ:SABS)’s 12-Month Price Target Is Now Set At 8.
In last trading session, SAB Biotherapeutics Inc (NASDAQ:SABS) saw 88282.0 shares changing hands with its beta currently measuring 0.47. Company’s recent per share price level
